New approaches to diagnosing and treating Crohn's disease


Cite item

Full Text

Abstract

The paper presents current views on the diagnosis and medical treatment of Crohn's disease (CD). It considers the present-day principles in the classification, evaluation of the severity of the disease, and its diagnostic criteria. There are actual medical treatment regimens for CD, regulated by the project of Russian clinical guidelines for the diagnosis and treatment of CD in adults (2013), which were drawn up by leading Russian experts relying on the European evidence-based consensus on the diagnosis and management of CD (2010). Promising treatment options for CD, which affect the key molecules of the pathogenesis of this disease, are considered.

Full Text

Новые подходы к диагностике и лечению болезни Крона. - Аннотация. Представлены современные взгляды на диагностику и консервативное лечение болезни Крона (БК). Рассмотрены современные принципы классификации, оценки тяжести и диагностические критерии рассматриваемого заболевания. Приведены актуальные схемы консервативной терапии БК, регламентированные проектом Российских клинических рекомендаций по диагностике и лечению БК у взрослых (2013), составленных ведущими отечественными экспертами на основании Европейского доказательного консенсуса по диагностике и лечению БК (2010). Рассмотрены перспективные методы лечения больных БК, влияющие на ключевые молекулы патогенеза данного заболевания.
×

About the authors

I V Maev

D N Andreev

Email: dna-mit8@mail.ru

References

  1. Парфенов А.И. Болезнь Крона: к 80-летию описания. Тер арх. 2013; 8: 35-42.
  2. Sands B.E., Siegel C.A. Crohn's disease. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger & Fordtran's Gastrointestinal and Liver Disease. 9th ed. Philadelphia, Pa: Saunders Elsevier; 2010: chap 111.
  3. Рекомендации Российской гастроэнтерологической ассоциации по лечению болезни Крона у взрослых (проект). Рос журн гастроэнтерол гепатол колопроктол 2012; 6: 66-82.
  4. Burisch J., Munkholm P. Inflammatory bowel disease epidemiology. Curr Opin Gastroenterol 2013; 29 (4): 357-362.
  5. Molodecky N.A., Soon I.S., Rabi D.M. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142 (1): 46-54.
  6. Kappelman M.D., Rifas-Shiman S.L., Kleinman K. et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007; 5:1424-1429.
  7. Ponder A., Long M.D. A clinical review of recent findings in the epidemiology of inflammatory bowel disease. Clin Epidemiol 2013; 5:237-247.
  8. Воробьев Г.И., Халиф И.Л. Неспецифические воспалительные заболевания кишечника. М: Миклош 2008.
  9. Bernstein C.N., Wajda A., Svenson L.W. et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 2006; 101:1559-1568.
  10. Barrett J.C., Hansoul S., Nicolae D.L. et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008; 40: 955-962.
  11. Lee Y.H., Song G.G. Pathway analysis of a genome-wide association study of ileal Crohn's disease. DNA Cell Biol 2012; 31 (10): 1549-1554.
  12. Tsianos E.V., Katsanos K.H., Tsianos V.E. Role of genetics in the diagnosis and prognosis of Crohn's disease. World J Gastroenterol 2012; 18 (2): 105-118.
  13. Маев И.В., Андреев Д.Н. Молекулярно-генетические механизмы развития болезни Крона. Мол мед 2014; 3: 21-27.
  14. Hugot J.P., Chamaillard M., Zouali H. et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603.
  15. Ogura Y., Bonen D.K., Inohara N. et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-606.
  16. Girardin S.E., Boneca I.G., Viala J. et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003; 278 (11): 8869-8872.
  17. Grimes C.L., Ariyananda Lde Z., Melnyk J.E., O'Shea E.K. The innate immune protein Nod2 binds directly to MDP, a bacterial cell wall fragment. J Am Chem Soc 2012; 134 (33):13535-13537.
  18. Maev I.V., Andreev D.N. Role of mutations in NOD2/CARD15, ATG16L1, and IRGM in the pathogenesis of Crohn's disease. Intern J Biomed 2014; 4 (1): 7-10.
  19. Maev I.V., Andreev D.N. Moderne vedute sul contributo delle mutazioni del gene NOD2/CARD15 nell'eziopatogenesi della malattia di Crohn. Italian Science Rev 2014; 3 (12): 122-126.
  20. Zhou Z., Lin X.Y., Akolkar P.N. et al. Variation at NOD2/CARD15 in familial and sporadic cases of Crohn's disease in the Ashkenazi Jewish population. Am J Gastroenterol 2002; 97: 3095-3101.
  21. Hampe J., Franke A., Rosenstiel P. et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007; 39 (2): 207-211.
  22. Rioux J.D., Xavier R.J., Taylor K.D. et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007; 39: 596-604.
  23. Cooney R., Baker J., Brain O. et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2010; 16 (1): 90-97.
  24. Travassos L.H., Carneiro L.A., Ramjeet M. et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010; 11: 55-62.
  25. Das K.M., Seril D.N. Mycobacterium avium Subspecies paratuberculosis in Crohn's disease: the puzzle continues. J Clin Gastroenterol 2012; 46 (8): 627-628.
  26. Smith E.J., Thompson A.P., O'Driscoll A., Clarke D.J. Pathogenesis of adherent-invasive Escherichia coli. Future Microbiol 2013; 8 (10): 1289-1300
  27. Duerr R.H., Taylor K.D., Brant S.R. et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314 (5804): 1461-1463.
  28. Siakavellas S.I., Bamias G. Role of the IL-23/IL-17 axis in Crohn's disease. Discov Med 2012; 14 (77): 253-262.
  29. Polgar N., Csongei V., Szabo M. et al. Investigation of JAK2, STAT3 and CCR6 polymorphisms and their gene-gene interactions in inflammatory bowel disease. Int J Immunogenet 2012; 39 (3): 247-252.
  30. Конович Е.А., Халиф И.Л., Шапина М.В. Иммунопатогенез воспалительных заболеваний кишечника. Рос журн гастроэнтерол гепатол колопроктол 2013; 4: 69-78.
  31. Marcuzzi A., Bianco A.M., Girardelli M. et al. Genetic and functional profiling of Crohn's disease: autophagy mechanism and susceptibility to infectious diseases. Biomed Res Int 2013; 2013: 297501.
  32. Jess T., Riis L., Vind I. et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: A population-based study from Copenhagen, Denmark. Inflamm. Bowel Dis 2007; 13: 481-489.
  33. Annunziata M.L., Caviglia R., Papparella L.G., Cicala M. Upper gastrointestinal involvement of Crohn's disease: a prospective study on the role of upper endoscopy in the diagnostic work-up. Dig Dis Sci 2012; 57: 1618.
  34. Silverberg M.S., Satsangi J., Ahmad T. et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 (suppl. A): 5-36.
  35. Cosnes J., Cattan S., Blain A. et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-250.
  36. Best W.R., Becktel J.M., Singleton J.W., Kern F. Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70 (3): 439-444.
  37. Pimentel M., Chang M., Chow E.J. et al. Identification of a prodromal period in Crohn's disease but not ulcerative colitis. Am J Gastroenterol 2000; 95: 3458.
  38. Burgmann T., Clara I., Graff L. et al. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis - how much is irritable bowel syndrome? Clin Gastroenterol Hepatol 2006; 4: 614.
  39. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-429.
  40. Ingle S.B., Loftus E.V. Jr. The natural history of perianal Crohn's disease. Dig Liver Dis 2007; 39 (10): 963-969.
  41. Yamaguchi A., Matsui T., Sakurai T. et al. The clinical characteristics and outcome of intraabdominal abscess in Crohn's disease. J Gastroenterol 2004; 39: 441-448.
  42. Гастроэнтерология. Национальное руководство. Под ред. В.Т. Ивашкина, Т.Л. Лапиной. М: ГЭОТАР-Медиа 2008.
  43. Bernstein C.N., Blanchard J.F., Rawsthorne P., Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: A population-based study. Am J Gastroenterol 2001; 96: 1116-1122.
  44. Jose F.A., Garnett E.A., Vittinghoff E. et al. Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 63-68.
  45. Vavricka S.R., Brun L., Ballabeni P. et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 2011; 106: 110-119.
  46. Lapidus A., Bernell O., Hellers G. et al. Clinical course of colorectal Crohn's disease: a 35-year follow-up study of 507 patients. Gastroenterology 1998; 114: 1151-1160.
  47. Baumgart D.C., Sandborn W.J. Crohn's disease. Lancet 2012; 380 (9853): 1590-1605.
  48. Lennard-Jones J.E., Shivananda S. Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. EC-IBD Study Group. Eur J Gastroenterol Hepatol 1997; 9 (4): 353-359.
  49. Panés J., Bouzas R., Chaparro M. et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther 2011; 34: 125-145.
  50. Lin M.F., Narra V. Developing role of magnetic resonance imaging in Crohn's disease. Curr Opin Gastroenterol 2008; 24: 135.
  51. Dotan I. Serologic markers in inflammatory bowel disease: tools for better diagnosis and disease stratification. Expert Rev Gastroenterol Hepatol 2007; 1: 265.
  52. Mosli M., Al Beshir M., Al-Judaibi B. et al. Advances in the diagnosis and management of inflammatory bowel disease: Challenges and uncertainties. Saudi J Gastroenterol 2014; 20 (2): 81-101.
  53. Vermeire S., Van Assche G., Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 661.
  54. Solem C.A., Loftus E.V., Tremaine W.J. Correlation of C-reactive protein (CRP) with clinical, radiographic, and endoscopic activity in inflammatory bowel disease (abstract). Gastroenterology 2004; 26 (Suppl): A477.
  55. Chamouard P., Richert Z., Meyer N. et al. Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 882.
  56. Boirivant M., Leoni M., Tariciotti D. et al. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol 1988; 10: 401.
  57. Consigny Y., Modigliani R., Colombel J.F. Biological markers of short term relapse in Crohn's disease (abstract). Gastroenterology 2001; 20:A53.
  58. Jürgens M., Mahachie John J.M., Cleynen I. et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011; 9: 421.
  59. Kuna A.T. Serological markers of inflammatory bowel disease. Biochem Med (Zagreb). 2013; 23 (1): 28-42.
  60. Peeters M., Joossens S., Vermeire S. et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001; 96:730.
  61. Mow W.S., Vasiliauskas E.A., Lin Y.C. et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004; 126: 414.
  62. Turner D., Leach S.T., Mack D. et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: A prospective multicentre comparison of predicting outcomes and monitoring response. Gut 2010; 59: 1207-1212.
  63. van Rheenen P.F., Van de Vijver E., Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341: c3369.
  64. Carter M.J., Lobo A.J., Travis S.P. IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53 (Suppl 5): V1-V16.
  65. Steinhart A.H., Ewe K., Griffiths A.M. et al. Corticosteroids for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2003 (4): CD000301.
  66. Dignass A., Van Assche G., Lindsay J.O. et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 2010; 4 (1): 28-62.
  67. Проект клинических рекомендаций по диагностике и лечению взрослых пациентов с болезнью Крона. Колопроктология 2013; 3: 22-38.
  68. Bar-Meir S., Chowers Y., Lavy A. et al. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology 1998; 115: 835-840.
  69. Халиф И.Л., Белоусова Е.А. Консервативная терапия воспалительных заболеваний кишечника в схемах: пособие для врачей. М: Форте принт 2014.
  70. Tromm A., Bunganic I., Tomsova E. et al. Double-blind, double-dummy, randomised, multicentre study to compare the efficacy and safety of oral budesonide (9mg) and oral mesalazine (4.5g) in moderately active Crohn's disease patients. Gastroenterology 2009; 139 (Suppl. 1): 391.
  71. Hanauer S.B., Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004; 2: 379-388.
  72. Sandborn W.J., Feagan B.G., Lichtenstein G.R. Medical management of mild to moderate Crohn's disease: Evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther 2007; 26: 987-1003.
  73. Белоусова Е.А. Рекомендации по диагностике и лечению взрослых пациентов с болезнью Крона (2013). Фарматека 2013; 14: 34-43.
  74. Toussirot E. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets 2012; 11 (2): 159-168.
  75. Mannon P.J., Fuss I.J., Mayer L. et al. The Anti-IL-12 Crohn's Disease Study Group. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004; 351: 2069-2079.
  76. Sandborn W.J., Feagan B.G., Fedorak R.N. et al. The Ustekinumab Crohn's Disease Study Group. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008; 135: 1130-1141.
  77. Khanna R., Feagan B.G. Ustekinumab for the treatment of Crohn's disease. Immunotherapy 2013; 5 (8): 803-815.
  78. Mozaffari S., Nikfar S., Abdolghaffari A.H., Abdollahi M. New biologic therapeutics for ulcerative colitis and Crohn's disease. Expert Opin Biol Ther 2014; 14 (5): 583-600.
  79. Thomas S., Baumgart D.C. Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology 2012; 20 (1): 1-18.
  80. Bamias G., Clark D.J., Rivera-Nieves J. Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease. Curr Drug Targets 2013; 14 (12):1490-500.
  81. Berlin C., Berg E.L., Briskin M.J. et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell. 1993; 74: 185-195.
  82. Briskin M., Winsor-Hines D., Shyjan A. et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997; 151: 97-110.
  83. Adams D.H., Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol 2006; 6: 244-251.
  84. Sakuraba A., Keyashian K., Correia C. et al. Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis 2013; 19 (3): 621-626.
  85. Toussirot E., Bereau M. The Risk of Progressive Multifocal Leukoencephalopathy Under Biological Agents Used in the Treatment of Chronic Inflammatory Diseases. Inflamm Allergy Drug Targets. 2014; in press.
  86. Soler D., Chapman T., Yang L.L. et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009; 330: 864-875.
  87. Sandborn W.J., Feagan B.G., Rutgeerts P. et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369 (8): 711-721.
  88. Lobatón T., Vermeire S., Van Assche G., Rutgeerts P. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2014; 39 (6): 579-594.

Copyright (c) 2014 Maev I.V., Andreev D.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies